We are live on ! Find out more

LTGO

Latigo Biotherapeutics

LTGO

Market cap $869M

13.11 USD

+0.18

1.39%

At close Updated Nov 13, 4:00 PM EST

Pre-market

After hours

13.11

0.00

0%

1 day

1.39%

5 days

4.13%

1 month

-16.55%

3 months

-34.65%

6 months

-28.16%

Year to date

-28.16%

1 year

-28.16%

5 years

-28.16%

10 years

-28.16%

About: Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 16.7%

Neutral 83.3%

Negative 0%

Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027

Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Latigo Biotherapeutics Announces CEO Transition to Support the Company's Next Phase of Growth

Todd N. Smith, a seasoned executive with deep experience commercializing pain therapies, appointed as president and chief executive officer to lead Latigo through planned late-stage development and commercialization of the Company's pipeline of non-opioid pain treatment programs

Latigo Biotherapeutics Announces CEO Transition to Support the Company's Next Phase of Growth

Latigo Biotherapeutics to Participate in Upcoming Investor Conferences in November

THOUSAND OAKS, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (Nasdaq: LTGO), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced that management will participate in the following investor conferences: Guggenheim 3 rd Annual Healthcare Innovation Conference – Boston, MA Fireside chat on Tuesday, November 10, 2026, at 8:30 a.m.

Latigo Biotherapeutics to Participate in Upcoming Investor Conferences in November

Vertex Built The NaV1.8 Market, Latigo May Be The One To Profit From It

Latigo Biotherapeutics is undervalued below IPO, with onzotrigine showing superior efficacy to Vertex's Journavx in acute pain. LTGO leverages Vertex's market groundwork, has pivotal-eligible Phase 2 data, and is funded into 2029, reducing near-term financing risk. Onzotrigine's Phase 3 bunionectomy trial is the key binary event; positive results could drive significant upside versus current market expectations.

Vertex Built The NaV1.8 Market, Latigo May Be The One To Profit From It

Primary Markets Group August IPO Update

August's seven U.S. IPOs matched the prior month's deal count, while aggregate proceeds declined modestly. The month saw $1.8 billion in total proceeds compared to the $3.0 billion raised in July and the $2.9 billion raised across seven IPOs in August 2025. Issuance was dominated by the healthcare sector, which priced five deals and accounted for over $1.4 billion of the total proceeds raised.

Primary Markets Group August IPO Update

Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Completed upsized initial public offering, including full exercise of the underwriters' option to purchase additional shares, raising gross proceeds of $397.4 million; together with existing cash expected to fund operations into 2029 The New England Journal of Medicine published positive onzotrigine (previously referred to as LTG-001) abdominoplasty clinical trial results in moderate-to-severe acute pain Expanded leadership team with appointment of Naomi Lowy, M.D., former deputy director of the FDA Division of Anesthesia, Addiction Medicine, and Pain Medicine, as senior vice president of global regulatory affairs THOUSAND OAKS, Calif.

Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

24/7 Wall Street

Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public

Latigo Biotherapeutics (NASDAQ:LTGO) arrived on public markets with the kind of reception biotech bankers dream about.

Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public

See News Rankings

Price charts implemented using Lightweight Charts™